SMMT · Nasdaq · CIK 0001599298

Summit Therapeutics Inc.

Summit Therapeutics Inc.’s most recent SEC filing in our snapshot is a Form DEF 14A filed on Oct 19, 2026. Its EDGAR record lists 15 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$1.1B
Form 4 filings on record, past 12 months
15

Company overview

Legal name (as filed)
Summit Therapeutics Inc.
Ticker
SMMT
SEC Central Index Key (CIK)
0001599298
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
MIAMI, FL
State or country of incorporation
—
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#802 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Summit Therapeutics Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$1.8MFY2021$705.0KFY2022$0FY2023$0FY2024n/aFY2025
Net income
-$88.6MFY2021-$78.8MFY2022-$614.9MFY2023-$221.3MFY2024-$1.1BFY2025
SMMT annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$1.8M$705.0K$0$0—
Net income-$88.6M-$78.8M-$614.9M-$221.3M-$1.1B
Diluted EPS-$0.67-$0.41-$0.99-$0.31-$1.44
Total assets$113.4M$664.2M$202.9M$435.6M$751.2M
Cash and equivalents$71.8M$348.6M$71.4M$104.9M$225.3M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SMMT latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 23, 202610-KAnnual report· period Dec 31, 2025Document · Index
Jul 23, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Sep 29, 20268-KMaterial agreement; Unregistered equity sale; Charter, bylaws or fiscal year change; Other events· period Sep 28, 2026Document · Index
Oct 19, 2026DEF 14ADefinitive proxy statement· period Nov 4, 2026Document · Index
Apr 30, 202020-FAnnual report of a foreign private issuer· period Dec 31, 2019Document · Index
Sep 17, 20206-KReport of a foreign private issuer· period Sep 17, 2020Document · Index

Recent SEC filings

The 40 newest documents filed by or about Summit Therapeutics Inc., by form type:

8-K ×174 ×7DEF 14A ×2PRE 14A ×210-Q ×2424B5 ×2UPLOAD ×2S-3ASR ×1DEFA14A ×1ARS ×1CORRESP ×110-K ×1S-8 ×1
SMMT recent filings
FiledFormWhat it isOriginal
Oct 19, 2026DEF 14ADefinitive proxy statement· period Nov 4, 2026Document · Index
Oct 14, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 8, 2026Document · Index
Oct 6, 2026PRE 14APRE 14A· period Oct 6, 2026Document · Index
Sep 29, 20268-KMaterial agreement; Unregistered equity sale; Charter, bylaws or fiscal year change; Other events· period Sep 28, 2026Document · Index
Sep 15, 20268-KOther events· period Sep 15, 2026Document · Index
Sep 14, 20268-KOther events· period Sep 13, 2026Document · Index
Sep 3, 20268-KOther events· period Sep 2, 2026Document · Index
Aug 26, 20268-KOther events· period Aug 25, 2026Document · Index
Aug 5, 20268-KOther events· period Aug 5, 2026Document · Index
Jul 23, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 23, 20268-KResults of operations; Regulation FD disclosure· period Jul 23, 2026Document · Index
Jul 23, 20268-KMaterial agreement· period Jul 23, 2026Document · Index
Jul 23, 2026424B5424B5Document · Index
Jul 22, 20268-KOther events· period Jul 22, 2026Document · Index
Jun 12, 20268-KShareholder vote results· period Jun 10, 2026Document · Index
Jun 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 11, 20268-KRegulation FD disclosure· period Jun 10, 2026Document · Index
Jun 10, 2026424B5424B5Document · Index
Jun 9, 2026S-3ASRSimplified registration statementDocument · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 3, 20268-KOther events· period Jun 2, 2026Document · Index
Jun 1, 20268-KOther events· period May 30, 2026Document · Index
Apr 30, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 30, 20268-KResults of operations· period Apr 30, 2026Document · Index
Apr 27, 2026UPLOADUPLOADDocument · Index
Apr 17, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 17, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 17, 2026DEF 14ADefinitive proxy statement· period Apr 17, 2026Document · Index
Apr 16, 2026CORRESPCORRESPDocument · Index
Apr 6, 2026PRE 14APRE 14A· period Apr 6, 2026Document · Index
Apr 2, 2026UPLOADUPLOADDocument · Index
Feb 23, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 23, 20268-KResults of operations; Regulation FD disclosure· period Feb 23, 2026Document · Index
Feb 23, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jan 29, 20268-KOther events· period Jan 29, 2026Document · Index
Jan 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 8, 2026Document · Index
Jan 12, 20268-KResults of operations; Regulation FD disclosure· period Jan 12, 2026Document · Index

Insider filing activity

15 Form 4 filings appear in Summit Therapeutics Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Florida

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001599298 and XBRL company facts. Summit Therapeutics Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.